x

Login

x

Sign Up


Register

CAPRELSA® (vandetanib) REMS Program | Advanced Medullary Thyroid Carcinoma (MTC)

Information for the CAPRELSA REMS Program. CAPRELSA® (vandetanib), a kinase inhibitor, approved by the FDA for symptomatic or progressive medullary thyroid cancer treatment in patients with unresectable locally advanced or metastatic disease.
Is this your site? Certify your site and update informations

VANDETANIBTOUCHPOINTS.COM on social networks



WHOIS
Add To Favorites

Relative websites

By continuing on this website, you agree that we may set cookies for website's reliability and submit to you Wiizl or third parties advertisement.  
Cut the Rope 2
Cut the Rope 2
Tap The Frog
Tap The Frog
FRUIT SLOTS
FRUIT SLOTS
MEGA SLOTS
MEGA SLOTS
1941 FROZEN FRONT
1941 FROZEN FRONT
Cut the Rope
Cut the Rope